10-K Decoder · All companies

ARS Pharmaceuticals, Inc.

SPRY · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$84.3M$89.2M−5.5%
Operating income−$179M−$3.08M−5,726%
Net income−$171M$8.00M

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026

$Q3 2026Year earlierChange
Revenue$37.7M$32.5M+16.0%
Operating income−$34.2M−$53.2M+35.7%
Net income−$35.6M−$51.2M+30.5%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was ARS Pharmaceuticals's revenue in FY2025?
$84.3M in FY2025 (Fiscal year ended Dec 31, 2025), −5.5% vs $89.2M a year earlier, per its 10-K filed Mar 2026.
Was ARS Pharmaceuticals profitable in FY2025?
No: net income was −$171M and operating income −$179M in FY2025.
What was ARS Pharmaceuticals's revenue in Q3 2026?
$37.7M (+16.0% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.